Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions
Abstract The 2019 coronavirus disease (COVID‐19) pandemic has become a global crisis. In the immunopathogenesis of COVID‐19, SARS‐CoV‐2 infection induces an excessive inflammatory response in patients, causing an inflammatory cytokine storm in severe cases. Cytokine storm leads to acute respiratory distress syndrome, pulmonary and other multiorgan failure, which is an important cause of COVID‐19 progression and even death. Among them, activation of inflammatory pathways is a major factor in generating cytokine storms and causing dysregulated immune responses, which is closely related to the severity of viral infection. Therefore, elucidation of the inflammatory signaling pathway of SARS‐CoV‐2 is important in providing otential therapeutic targets and treatment strategies against COVID‐19. Here, we discuss the major inflammatory pathways in the pathogenesis of COVID‐19, including induction, function, and downstream signaling, as well as existing and potential interventions targeting these cytokines or related signaling pathways. We believe that a comprehensive understanding of the regulatory pathways of COVID‐19 immune dysregulation and inflammation will help develop better clinical therapy strategies to effectively control inflammatory diseases, such as COVID‐19..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
MedComm - 3(2022), 3, Seite n/a-n/a |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yujie Jiang [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
COVID‐19 |
|---|
| doi: |
10.1002/mco2.154 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ029599997 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ029599997 | ||
| 003 | DE-627 | ||
| 005 | 20230307135849.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/mco2.154 |2 doi | |
| 035 | |a (DE-627)DOAJ029599997 | ||
| 035 | |a (DE-599)DOAJb1feac837ad441b3839c8257c2178f9e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Yujie Jiang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The 2019 coronavirus disease (COVID‐19) pandemic has become a global crisis. In the immunopathogenesis of COVID‐19, SARS‐CoV‐2 infection induces an excessive inflammatory response in patients, causing an inflammatory cytokine storm in severe cases. Cytokine storm leads to acute respiratory distress syndrome, pulmonary and other multiorgan failure, which is an important cause of COVID‐19 progression and even death. Among them, activation of inflammatory pathways is a major factor in generating cytokine storms and causing dysregulated immune responses, which is closely related to the severity of viral infection. Therefore, elucidation of the inflammatory signaling pathway of SARS‐CoV‐2 is important in providing otential therapeutic targets and treatment strategies against COVID‐19. Here, we discuss the major inflammatory pathways in the pathogenesis of COVID‐19, including induction, function, and downstream signaling, as well as existing and potential interventions targeting these cytokines or related signaling pathways. We believe that a comprehensive understanding of the regulatory pathways of COVID‐19 immune dysregulation and inflammation will help develop better clinical therapy strategies to effectively control inflammatory diseases, such as COVID‐19. | ||
| 650 | 4 | |a COVID‐19 | |
| 650 | 4 | |a cytokine storm | |
| 650 | 4 | |a immunopathology | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a inflammatory pathways | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Tingmei Zhao |e verfasserin |4 aut | |
| 700 | 0 | |a Xueyan Zhou |e verfasserin |4 aut | |
| 700 | 0 | |a Yu Xiang |e verfasserin |4 aut | |
| 700 | 0 | |a Pedro Gutierrez‐Castrellon |e verfasserin |4 aut | |
| 700 | 0 | |a Xuelei Ma |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t MedComm |d Wiley, 2020 |g 3(2022), 3, Seite n/a-n/a |w (DE-627)DOAJ07863024X |x 26882663 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2022 |g number:3 |g pages:n/a-n/a |
| 856 | 4 | 0 | |u https://doi.org/10.1002/mco2.154 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/b1feac837ad441b3839c8257c2178f9e |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1002/mco2.154 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2688-2663 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2022 |e 3 |h n/a-n/a | ||